Filip Dubovsky - 14 Dec 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role: President, R&D
Signature: /s/ Mark Casey, Attorney-in-Fact
Issuer symbol: NVAX
Transactions as of: 14 Dec 2023
Net transactions value: +$8,336
Form type: 4
Filing time: 18 Dec 2023, 17:00:29 UTC
Previous filing: 07 Nov 2023
Next filing: 26 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVAX	Common Stock	Options Exercise	$16,120	+2,833	+5.4%	$5.69	55,150	14 Dec 2023	Direct
transaction	NVAX	Common Stock	Tax liability	$7,784	-1,368	-2.5%	$5.69	53,782	14 Dec 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVAX	Restricted Stock Units	Options Exercise	$0	-2,833	-100%	$0.000000^*	0	14 Dec 2023	Common Stock	2,833		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2	The RSUs subject to this grant under the Plan vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment with the Company through such vesting date.